☰
✕

Chronic liver diseases therapeutics market

Chronic Liver Diseases Therapeutics Market, By Treatment Type Antiviral Drugs, By Disease Type, By Distribution type, And By Region (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa) -

Request Free Sample
  • Aug 2023
  • CMI4047
  • 180 Pages
  • Excel & Pdf
  • Pharmaceutical

The global chronic liver diseases therapeutics market is estimated to be valued at US$ 15.2 billion in 2023 and is expected to exhibit a CAGR of  10.9% during the forecast period (2023-2030).

Analysts’ Views on Global Chronic Liver Diseases Therapeutics Market:

Increasing prevalence of and awareness about chordoma disease, rising geratic population, and new drugs releases and strategic efforts by prominent market competitors are favorably impacting the market's growth. The high prevalence of cancer, favorable health reimbursement, and increased awareness regarding cancer among people and clinicians is a major factor in the chronic liver diseases therapeutics market, thereby contributing to the market growth.

Figure 1. Global Chronic Liver Diseases Therapeutics Market Share (%), By Treatment Type, 2023

Global Chronic Liver Diseases Therapeutics Market– Driver

Increasing cancer cases such as liver cancer

Increasing cancer cases such as liver cancer is expected to propel growth of the global chronic liver diseases therapeutics market over the forecast period. For instance, according to an article published in the World Health Organization, in February 2022, the age-standardized point prevalence and annual incidence rates of cancer were 246.6 and 14.9 in 2021, which increased by 7.4% and 8.2% from 1990, respectively. Cancer is a leading cause of death worldwide, accounting for nearly 10 billion deaths in 2020. As per the national orgniasation of rare disorders reported, the incidence of liver is estimated approximately 1 per 1,000,000 people. About 300 cases of chordoma are diagnosed in the U.S. each year.

Increasing research & development activities for the treatment of chronic liver diseases

Increasing research & development activities for the treatment of chronic liver diseases is expected to drive growth of the global chronic liver diseases therapeutics market over the forecast period. For instance, in January 2022, Madrigal Pharmaceuticals, Inc. announced positive top line clinical data from the placebo-controlled, double-blind portion of its phase 3 MAESTRO-NAFLD (non-alcoholic fatty liver disease) safety study of resmetirom.

Figure 2. Global Chronic Liver Diseases Therapeutics Market Share (%), by Region, 2023

Global Chronic Liver Diseases Therapeutics Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global chronic liver diseases therapeutics market over the forecast period. north america is estimated to hold 34.1% of the market share in 2023. The global chronic liver diseases therapeutics market is expected to witness significant growth in the coming years, driven by the high prevalence of cancer, favorable health reimbursement, and increased awareness, For instance, according to the press release in February 2020, by imaware, provides laboratory testing for wellness monitoring, informational, and educational use in North America, announced the launch of the At-Home Cancer Screening Test, designed by healthcare company Micro drop. The imaware test for cancer uses just a few drops of blood to detect unique biomarkers as well as two additional drugs to provide more comprehensive results. These kinds of developments in the healthcare system and rising health expenditures, as well as increased knowledge of advanced cancer treatments, are fueling the Chronic Liver Diseases Therapeutics market in North America.

Global Chronic Liver Diseases Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on the global Chronic Liver Diseases Therapeutics market. The COVID-19 outbreak affected the market's growth adversely in its preliminary phase; however, the number of cancer patients increased, and so has the demand for the chordoma disease market. For instance, according to an article published in February 2022 on PubMed Central, “COVID-19 and Cancer Cross talk: Emerging Association, Therapeutic Options and Challenges”, explains that the management of cancer patients in the COVID-19 context is a difficult task in and of itself. Even though online consultations are advisable with patients who are having stable cancer.

Chronic Liver Diseases Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2022 Market Size in 2023: US$ 15.2 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 to 2030
Forecast Period 2023 to 2030 CAGR: 10.9% 2030 Value Projection: US$ 31.3 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Treatment Type Antiviral Drugs: Antiviral Drugs, Immunosuppressants, Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy
  • By Disease Type: Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liver Disease (NAFLD), Cancer, Genetic Disorders, Others
  • By Distribution type: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 
Companies covered:

Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., MAX BioPharma, Inc.
Growth Drivers:
  • Increasing cancer cases such as liver cancer  
  • Increasing research & development activities for the treatment of chronic liver diseases
Restraints & Challenges:
  • Chemotherapeutic drugs approved for the treatment of Liver are Showing side effects

Global Chronic Liver Diseases Therapeutics Market Segmentation:

The global chronic liver diseases therapeutics market report is segmented By Treatment Type, By Disease Type, By Distribution type, and By Region.

By Treatment Type, the market is segmented into Antiviral drugs, immunosuppressant’s, vaccines, immunoglobulin’s, corticosteroids, targeted therapy, and chemotherapy. Out of which, the antiviral drugs  is expected to hold a dominant position in the global chronic liver diseases therapeutics market during the forecast period and this is attributed to awareness about liver diseases.

By Disease Type, the market is segmented into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (nafld), cancer, genetic disorders, and others. Out of which, the Hepatitis is expected to dominate the market over the forecast period and this is attributed to increasing heavy alcohol use, toxins, some medications, and certain medical conditions.

By Distribution Channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, Hospital pharmacies is expected to dominate the market over the forecast period and this is attributed to prevention, diagnosis, multidisciplinary treatment, supportive care, research and education.

Among all the segmentations, the treatment type segment expected to dominate the market over the forecast period and this is attributed to the block cancer growth in  liver disease is which is expected boost the growth of chronic liver diseases therapeutics market over the forecast period.

Global Chronic Liver Diseases Therapeutics Market Cross Sectional Analysis:

Key players are making Chronic Liver Diseases Therapeutics with proper drug treatment emerging economies is also expected to boost demand chronic liver diseases therapeutics market in North America region. For instance, in October 2020, Myriad Genetic Laboratories, Inc., a genetic testing and precision medicine company based in Salt Lake City, Utah, U.S., introduced Myriad's EGFR (estimated glomerular filtration rate) inhibitor treatment method from the Japanese Ministry of Health, Labor, and Welfare to be utilized as a partnered treatment.

Global Chronic Liver Diseases Therapeutics Market: Key Developments

In September 2021, Astellas is a multinational pharmaceutical company in Japan, announced that it has voluntarily paused screening and dosing of additional participants in its ASPIRO clinical trial evaluating AT132 in patients with X-linked Myotubular Myopathy (XLMTM). This decision follows the reporting of a recent serious adverse event (SAE) in a study participant due to abnormal liver function tests (LFTs) observed in the weeks following dosing of the AT132 investigational gene therapy product at a lower dose (1.3x1014 vg/kg). Astellas voluntarily halted screening and dosing, reported the SAE to regulatory agencies, and is engaged in dialogue with regulators about this SAE.

On May 13, 2023, Astellas Pharma Inc., a multinational pharmaceutical company in Japan, announced that the U.S. Food and Drug Administration (FDA) has approved VEOZAHTM (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause1 on May 12. VEOZAH is the first non-hormonal neurokinin 3 (NK3) receptor antagonist approved to treat VMS due to menopause.

In October 2022, Bristol Myers Squibb, a  biological and pharmaceutical research, producing the antipsychotic Abilify company, announced new results from the POETYK PSO long-term extension (LTE) trial demonstrating clinical efficacy was maintained with continuous Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis. This analysis assessed patients from the pivotal POETYK PSO-1 trial transitioned into the LTE trial. At 112 weeks of Sotyktu treatment, modified non-responder imputation (mNRI) response rates were 82.4% for Psoriasis Area and Severity Index (PASI) 75, 55.2% for PASI 90 and 66.5% for static Physician's Global Assessment (sPGA) 0/1.

In June 2022, Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, announced that more than 80 abstracts will be presented at the International Liver Congress (ILC) 2022, placed from June 22-26, 2022. Key oral presentations will include Week 48 primary endpoint data from the Pivotal Phase 3 program of Hepcludex (bulevirtide) evaluating its efficacy and safety for the treatment of hepatitis delta virus (HDV) and the impact of the treatment on patient-reported outcomes.

On June 1, 2023, Myriad Genetics, Inc., a company of genetic testing and precision medicine, launched new studies and expansion of its Precise Oncology Solutions portfolio at the 2023 American Society of Clinical Oncology (ASCO).

On March 22, 2023, F. Hoffmann-La Roche Ltd (Roche), a biotechnology company that develops drugs and diagnostics to treat major diseases, announced that it has entered into a collaboration with Eli Lilly and Company, a pharmaceutical company headquartered in U.S. to support the development of Roche’s Elecsys Chronic Liver Diseases Therapeutics.

In November 2022, GSK plc, a multinational pharmaceutical and biotechnology company with global headquarters in London, announced the publication of positive end of study results from the B-Clear phase IIb trial evaluating the safety and efficacy of bepirovirsen for the treatment of chronic hepatitis B (CHB) in the New England Journal of Medicine. The results showed that treatment with bepirovirsen, an investigational antisense oligonucleotide treatment, resulted in sustained clearance of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA both in patients on concurrent nucleoside/nucleotide analogues (NA) and patients not-on-NA therapy.

In June 2022, GSK plc, a multinational pharmaceutical and biotechnology company with global headquarters in London, announced promising interim results from the B-Clear phase IIb trial showing that bepirovirsen, an investigational antisense oligonucleotide treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA after 24 weeks’ treatment in people with chronic hepatitis B (CHB).

In March 2022, Invitae, a medical genetics company, announced full access to its Personalized Cancer Monitoring (PCMTM) platform to help detect minimal or molecular residual disease (MRD) in patients with solid tumors. Invitae PCM uses a novel set of personalized assays based on a patient's tumor to detect circulating tumor DNA (ctDNA) in blood, offering the ability to perform risk stratification, response assessment to treatment and detection of cancer recurrence, based on recent studies.In November 2022, Arrowhead Pharmaceuticals Inc., develops medicines that treat intractable diseases by silencing the genes, entered a drug development deal with GlaxoSmithKline Plc (GSK.L), a multinational pharmaceutical and biotechnology company with global headquarters in London, under which the British drugmaker will develop and market Arrowhead's potential treatment for patients with fatty liver disease NASH.

Global Chronic Liver Diseases Therapeutics Market: Key Trends

Application of biomarker test for diagnosing liver disease

Application of biomarker test for diagnosing  liver disease is expected to propel growth of the global chronic liver diseases therapeutics market over the forecast period. Major players in the market are focused on adopting partnership strategies to expand its product portfolio. Presently, there is no drugs available for the diagnosis of chordoma disease. However, anti–cyclic citrullinated peptide (anti–CCP) antibodies test require more refinement to improve its clinical utility. For instance, in March 2020, WorldCare Clinical, LLC, an independent contract research organization offering imaging in clinical trials, partnered with Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, to offer imaging service following U.S. FDA approval of Navidea’s cancer diagnostic. Navidea’s strategy is to deliver novel products and advancing the company’s pipeline through global partnering with WorldCare Clinical, LLC.

Global Chronic Liver Diseases Therapeutics Market: Restraint

Chemotherapeutic drugs approved for the treatment of liver are showing side effects

Chemotherapeutic drugs approved for the treatment of liver are not always effective and have several side effects such as nausea, headache, and hair loss is expected to hamper the growth of the global chronic liver diseases therapeutics market. For instance, according to an article published in the National library of medicine, on February 27, 2023, reported antimetabolites have a several side effects such as dose-limiting myelosuppression. Toxic levels of 5-fluorouracil occur in patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency or drug overdose. This lead to cardiac dysfunction, colitis, neutropenia, and encephalopathy.

Key market players are focusing on safety and efficacy of drugs.

Global Chronic Liver Diseases Therapeutics Market- Key Players

Major players operating in the global Chronic Liver Diseases Therapeutics market include Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.

*Definition: Chronic liver disease is a gradual deterioration of liver functions. Liver function comprises the excretion of bile, detoxification of harmful products of metabolism, production of clotting factors, and other proteins. Chronic liver disease is a constant process of destruction, inflammation, and regeneration of the liver parenchyma, which leads to fibrosis and cirrhosis. The causes of chronic liver diseases include alcohol abuse, toxins, infection, autoimmune diseases, genetic and metabolic disorders.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Treatment Type
      • Market Snippet, By Disease Type
      • Market Snippet, By Distribution type
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Recent Drug Launches
    • Epidemiology
    • Merger, Acquisition, and Collaborations
    • Regulatory Scenario
    • Key Developments
    • PEST Analysis
  4. Global Chronic Liver Diseases Therapeutics  Market– COVID-19 Impact Analysis
    • Economic Impact
    • COVID-19 Epidemiology
    • Impact on Supply and Demand
  5. Global Chronic Liver Diseases Therapeutics Market, By Treatment Type, 2018–2030 (US$ Bn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2019–2030
      • Segment Trends
    • Antiviral Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
      • Segment Trends
    • Immunosuppressants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
      • Segment Trends
    • Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
      • Segment Trends
    • Immunoglobulins
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
      • Segment Trends
    • Corticosteroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
      • Segment Trends
    • Targeted Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
      • Segment Trends
    • Chemotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
      • Segment Trends
  6. Global Chronic Liver Diseases Therapeutics  Market, By Disease Type, 2018–2030 (US$ Bn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2019–2030
      • Segment Trends
    • Hepatitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
    • Autoimmune Diseases
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
    • Non-alcoholic Fatty Liver Disease (NAFLD)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
    • Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
    • Genetic Disorders
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
  7. Global Chronic Liver Diseases Therapeutics  Market, By Distribution type, 2018–2030 (US$ Bn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2019–2030
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
  8. Global Chronic Liver Diseases Therapeutics  Market, By Regions, 2018–2030 (US$ Bn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2019–2030
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Country, and Y-o-Y Growth 2018–2030, (US$ Bn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Country, and Y-o-Y Growth 2018–2030, (US$ Bn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Country, and Y-o-Y Growth 2018–2030, (US$ Bn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Country, and Y-o-Y Growth 2018–2030, (US$ Bn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Country, and Y-o-Y Growth 2018–2030, (US$ Bn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2018–2030, (US$ Bn)
      • Market Size and Forecast, By Country, and Y-o-Y Growth 2018–2030, (US$ Bn)
        • North Africa
        • Central Africa
        • South Africa
  9. Competitive Landscape
    • Company Profiles
      • Astellas Pharma Inc
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Bristol-Myers Squibb
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Gilead Sciences
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • GlaxoSmithKline Plc
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      •  F. Hoffmann-La Roche Ltd.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      •  Merck & Co. Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Sanofi S.A
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Takeda Pharmaceutical
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Valeant Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Watson Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Theratechnologies Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Alnylam Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Protagonist Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Dicerna Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Endo International
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Provectus Biopharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • MAX BioPharma, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 30 market data tables and 24 figures on “Chronic Liver Diseases Therapeutics Market– Global forecast to 2030

Detailed Segmentation:

  • Global Chronic Liver Diseases Therapeutics Market, By Treatment Type:
    • Antiviral drugs
    • Immunosuppressants
    • Vaccines
    • Immunoglobulins
    • Corticosteroids
    • Targeted Therapy
    • Chemotherapy
  • Global Chronic Liver Diseases Therapeutics Market, By Disease Type:
    • Hepatitis
    • Autoimmune Diseases
    • Non-alcoholic Fatty Liver Disease (NAFLD)
    • Cancer
    • Genetic Disorders
    • Others
  • Global Chronic Liver Diseases Therapeutics Market, By Distribution type:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Chronic Liver Diseases Therapeutics, By Region:
    • North America
      • By Treatment Type:
        • Antiviral drugs
        • Immunosuppressants
        • Vaccines
        • Immunoglobulins
        • Corticosteroids
        • Targeted Therapy
        • Chemotherapy
      • By Disease Type:
        • Hepatitis
        • Autoimmune Diseases
        • Non-alcoholic Fatty Liver Disease (NAFLD)
        • Cancer
        • Genetic Disorders
        • Others
      • By Distribution type:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Treatment Type:
        • Antiviral drugs
        • Immunosuppressants
        • Vaccines
        • Immunoglobulins
        • Corticosteroids
        • Targeted Therapy
        • Chemotherapy
      • By Disease Type:
        • Hepatitis
        • Autoimmune Diseases
        • Non-alcoholic Fatty Liver Disease (NAFLD)
        • Cancer
        • Genetic Disorders
        • Others
      • By Distribution type:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Treatment Type:
        • Antiviral drugs
        • Immunosuppressants
        • Vaccines
        • Immunoglobulins
        • Corticosteroids
        • Targeted Therapy
        • Chemotherapy
      • By Disease Type:
        • Hepatitis
        • Autoimmune Diseases
        • Non-alcoholic Fatty Liver Disease (NAFLD)
        • Cancer
        • Genetic Disorders
        • Others
      • By Distribution type:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Treatment Type:
        • Antiviral drugs
        • Immunosuppressants
        • Vaccines
        • Immunoglobulins
        • Corticosteroids
        • Targeted Therapy
        • Chemotherapy
      • By Disease Type:
        • Hepatitis
        • Autoimmune Diseases
        • Non-alcoholic Fatty Liver Disease (NAFLD)
        • Cancer
        • Genetic Disorders
        • Others
      • By Distribution type:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Treatment Type:
        • Antiviral drugs
        • Immunosuppressants
        • Vaccines
        • Immunoglobulins
        • Corticosteroids
        • Targeted Therapy
        • Chemotherapy
      • By Disease Type:
        • Hepatitis
        • Autoimmune Diseases
        • Non-alcoholic Fatty Liver Disease (NAFLD)
        • Cancer
        • Genetic Disorders
        • Others
      • By Distribution type:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Treatment Type:
        • Antiviral drugs
        • Immunosuppressants
        • Vaccines
        • Immunoglobulins
        • Corticosteroids
        • Targeted Therapy
        • Chemotherapy
      • By Disease Type:
        • Hepatitis
        • Autoimmune Diseases
        • Non-alcoholic Fatty Liver Disease (NAFLD)
        • Cancer
        • Genetic Disorders
        • Others
      • By Distribution type:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global chronic liver diseases therapeutics market during the forecast period (2023-2030)?

The global chronic liver diseases therapeutics market is estimated to be valued at US$ 15.2 billion in 2023 and is expected to exhibit a CAGR of 10.9% between 2023 and 2030.

What are the major factors driving the market growth?

Increasing cancer cases such as liver cancer  and increasing research & development activities for the treatment of chronic liver diseases is expected to drive the market growth.

Which is the leading treatment type segment in the market?

Antiviral Drugs is the leading segment in the market.

What are the key factors hampering the growth of the market?

Chemotherapeutic drugs approved for the treatment of chordoma are showing side effcts  expected to hinder the market over the forecast period.

Which are the major players operating in the market?

Major Players including Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.
Buy Now with Special Discount
Customize Now